Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Norethindrone/Ethinyl Estradiol Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)

NCT00475189
View directory record Official record
Conditions
Pelvic Pain, Headaches, Emotional
Interventions
loestrin 24/4 vs loestrin 1/20, loestrin 1/20
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

NCT00000897
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Danicopan

NCT04709094
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial

NCT00350480
View directory record Official record
Conditions
Uterine Hemorrhage, Menorrhagia
Interventions
Provera, Combination Birth Control pills
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

NCT00006133
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older · Female only
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 9:44 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

NCT07766369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

NCT06460948
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Oral Contraceptives on GABA and Neurosteroids

NCT00656318
View directory record Official record
Conditions
Healthy
Interventions
oral contraceptive pill (OCP; OCPs)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Results available

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

NCT01209143
View directory record Official record
Conditions
Solid Cancers
Interventions
Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptive (OC) Progestin Dose and Breast Proliferation

NCT00972439
View directory record Official record
Conditions
Oral Contraceptive
Interventions
Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon Fe®
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study

NCT00600106
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
1/10 NA/EE, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 1, 2026, 9:44 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

NCT02210702
View directory record Official record
Conditions
Postpartum Depressive Mood, Postpartum Sexual Function
Interventions
Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg
Drug
Lead sponsor
The Jones Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 1, 2026, 9:44 AM EDT
Recruiting Early Phase 1 Interventional

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

NCT07568509
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

NCT00704912
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

NCT01077505
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, Oral contraceptive (Brevicon)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 1, 2026, 9:44 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

NCT00999479
View directory record Official record
Conditions
Endometrioma
Interventions
Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chronic Pain Risk Associated With Menstrual Period Pain

NCT02214550
View directory record Official record
Conditions
Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
Interventions
cyclic microgestin 1/20, continuous microgestin 1/20
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
View directory record Official record
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Bleeding With Extended Administration of an Oral Contraceptive

NCT00338052
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone 1 mg / ethinyl estradiol 20 mcg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
25 Years to 40 Years · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Carmichael, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00391807
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone acetate/ethinyl estradiol
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
66
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00477633
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone/ethinyl estradiol
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
63
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

NCT01344369
View directory record Official record
Conditions
Healthy
Interventions
Norethindrone/Ethinyl Estradiol, FEMCON® Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

NCT04016753
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 1, 2026, 9:44 AM EDT